the Prevalence,Lipid Abnormalities, Clinical Trial
Official title:
Dyslipidemia International Survey - China
This cross-sectional, non-interventional, and observational study will assess the lipid
profile of patients who have been taking lipid-modifying drugs (i.e., proportion of patients
achieving treatment to goal according to national and international lipid management
guidelines) during a single visit to their physicians on an outpatient basis in 6
representative geo-economic regions in China: Northeast, North, East, South, Southwest, and
Northwest; and within each region, in three tiers of hospitals: tier 3 (primary or teaching
hospitals), tier 2 (secondary or city level hospitals), and tier 1 (community
hospitals/health centers). The investigators will primarily be cardiologists,
endocrinologists, neurologists, gerontologists, internists, or other physicians who are
representative of the general population of physicians managing patients with dyslipidemia
and/or at high risk for cardiovascular events likely to be treated with lipid-modifying
drugs. Demographic data, cardiovascular risk factors, a history of cardiovascular disease
and cardiovascular treatments will be documented in a single visit through patient clinical
examination and chart review.
DYSIS-China is part of a string of epidemiological studies that share the same master
protocol, which has been conducted in different countries mainly in Europe and Canada. The
analysis of the pooled studies including overall data and cross-country comparisons is the
subject of a distinct protocol.
n/a
Observational Model: Case-Only, Time Perspective: Cross-Sectional